RSV Prevention and Complications in Vulnerable Populations: A Comprehensive Study

The recent FDA approval of nirsevimab, a monoclonal antibody, may help prevent respiratory syncytial virus (RSV) in infants. Currently, there is no FDA-approved antiviral treatment for RSV, and the focus is on supportive care. RSV is the leading cause of infant hospitalizations, with 58,000-80,000 children under 5 years being hospitalized annually. Nirsevimab is the first prophylactic product indicated for the prevention of RSV lower respiratory tract disease in newborns and infants, potentially reducing hospitalizations and severe lung infections. Clinicians hope this monoclonal antibody will be a game changer in managing RSV in the most vulnerable population.